Arterial Hypertension, Pulmonary
Conditions
Brief summary
The purpose of this study is to learn what happens to macitentan and its active metabolite (aprocitentan) in the body of children aged between 1 month and 2 years.
Interventions
DRUGMacitentan
Macitentan will be administered orally.
Sponsors
Actelion
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Months to 2 Years
Healthy volunteers
No
Inclusion criteria
* Pulmonary arterial hypertension (PAH): 1) including participants with Down syndrome. Diagnosis must have been confirmed by (historical, any time before screening) right heart catheterization mean pulmonary arterial pressure (mPAP) greater than or equal to (\>=) 25 millimeter of mercury (mmHg), pulmonary arterial wedge pressure (PAWP) less than or equal to (=\<)15 mmHg, pulmonary vascular resistance index greater than (\>) 3 Wood units \* meter square (m\^2) where in the absence of pulmonary vein obstruction and/or significant lung disease PAWP can be replaced left atrium pressure or left ventricular end diastolic pressure (in the absence of mitral stenosis) assessed by heart catheterization. a) Idiopathic PAH, or b) Heritable PAH, or c) PAH associated with congenital heart disease: i) Eisenmenger syndrome (Qp/Qs less than (\<) 1.5 and saturation of peripheral oxygen ≤ 90 percent (%) measured by pulse oximetry at room air), or ii) Inoperable open left-to-right shunts (with a Pulmonary vascular resistance \[PVR\] \> 8 WU and Qp/Qs \<2), or iii) Co-incidental shunt (that is, not explaining hemodynamically the presence of PAH), or iv) Post-operative PAH (persisting/recurring/developing ≥ 6 months after repair of shunt), or d) Drug or toxin induced PAH, or e) PAH associated with Human immunodeficiency viruses (HIV) * World Health Organization Functional Class (WHO FC) I, II, or III * PAH-specific treatment-naive participants or participants on PAH specific monotherapy or combination of 2 therapies. Use of macitentan before or during screening is allowed * Body weight of greater than or equal to (\>=) 3.5 kilogram (kg) * Parent(s) (preferably both if available or as per local requirements) or participant's legally designated representative must sign an informed consent form (ICF) indicating that they understand the purpose of, and procedures required for, the study and is/are willing to allow the child to participate in the study
Exclusion criteria
* PAH due to portal hypertension, schistosomiasis, pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis * Persistent pulmonary hypertension of the newborn * The following congenital cardiac abnormalities: a) Cyanotic congenital cardiac lesions such as transposition of the great arteries, truncus arteriosus, pulmonary atresia with ventricular septal defect, unless operatively repaired and with no residual shunt. b) Univentricular heart and/or participants with Fontan-palliation * Pulmonary hypertension due to lung disease * Known diagnosis of bronchopulmonary dysplasia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Trough Concentration of Macitentan and its Active Metabolite Aprocitentan at Week 4 in Steady-State | Predose (at Week 4) | Trough concentration of macitentan and its active metabolite aprocitentan at week 4 in steady-state will be reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Serious Adverse Events (SAEs) | Up to 1.5 years | A SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and is a suspected transmission of any infectious agent via a medicinal product, is medically important. |
| Number of Participants with AEs Leading to Premature Discontinuation of Macitentan | Up to 1.5 years | Number of participants with AEs Leading to premature discontinuation of macitentan will be reported. |
| Number of Participants with Adverse Event of Special Interests (AESIs) | Up to 1.5 years | Number of participants with AESI will be reported. AEs considered to be of special interest are as hypotension, edema/fluid retention, hemoglobin decrease/anemia, liver events. |
| Number of Participants with Clinical Laboratory Abnormalities | Up to 1.5 years | Number of participants with clinical laboratory abnormalities (serum, chemistry and hematology) will be reported. |
| Number of Participants with Change from Baseline in Clinical laboratory Values. | Up to 1.5 years | Number of participants with change from baseline in clinical laboratory values will be reported. |
| Change from Baseline in Blood Pressure | Up to 1.5 years | Change from baseline in blood pressure will be reported. |
| Number of Participants with Adverse Events (AEs) | Up to 1.5 years | An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. |
| Change From Baseline in Body Weight | Up to 1.5 years | Change from baseline in body weight will be reported. |
| Change From Baseline in Length | Up to 1.5 years | Change from baseline in length will be reported. |
| Change from Baseline in Height | Up to 1.5 years | Change from baseline in height will be reported. |
| Plasma Concentration of Macitentan and its Active Metabolite (Aprocitentan) for Macitentan Naive Participants | At 2, 5, and 24 hours after the first dose of macitentan on Day 1 | Plasma concentrations of macitentan and its active metabolite (aprocitentan) after the first dose of macitentan for macitentan naive participants will be reported. |
| Trough Concentrations of Macitentan and its Active Metabolite Aprocitentan at Week 8 in Steady-State Conditions | Predose (at Week 8) | Trough concentrations of macitentan and its active metabolite aprocitentan at week 8 in steady-state conditions will be reported. |
| Change From Baseline in Heart Rate | Up to 1.5 years | Change from baseline in heart rate will be reported. |
Countries
Germany, Poland
Outcome results
None listed